Literature DB >> 26345688

Contraceptive practices and cervical screening in women with cystic fibrosis.

C Rousset Jablonski1, Q Reynaud2, M Perceval3, R Nove-Josserand3, S Durupt3, J C Lega2, I Durieu2.   

Abstract

STUDY QUESTION: Is gynaecological management of women with cystic fibrosis (CF) adequate? SUMMARY ANSWER: Gynaecological care (frequency of follow-up, cervical screening and contraceptive use among sexually active women) in women with CF fails to reach the recommended level. WHAT IS KNOWN ALREADY: Little is known about gynaecological follow-up and cervical screening in CF. Only few studies have described contraceptive practices in cohorts of CF women. STUDY DESIGN, SIZE, DURATION: We did a cross-sectional study in a cohort of 155 CF women attending the Lyon adult centre. Women attending the CF adult centre in 2014 completed a written questionnaire about their contraceptive choices, frequency of gynaecological follow-up and cervical screening. Other clinical data were collected from the CF adult centre registry. PARTICIPANTS/MATERIALS, SETTING,
METHODS: One hundred and twenty women (100%) answered the questionnaire, among whom two were post-menopausal (46 and 59 years of age), and five were pregnant. MAIN RESULTS AND THE ROLE OF CHANCE: Seventy-four per cent of the women declared they had undergone gynaecological follow-up (89% of the women with transplantation), and only 55% reported having at least one previous Pap smear test. Among the transplanted patients, only 58% had had a Pap smear test, despite immunosuppressive treatment. The overall rate of contraception was only 64% and in diabetic women, it was 61%. Among contraception users; 65% used oral contraception, predominantly combined estrogen-progestagen (47%); among diabetic patients, 26% used progestin-only contraception. Intrauterine device accounted for 10% of patients using contraception, and tubal ligation only 4%. LIMITATIONS, REASONS FOR CAUTION: This study is limited by its cross-sectional design. Despite an internal validation of the questionnaire showing an almost perfect agreement, the risk of recall bias has to be taken into account. WIDER IMPLICATIONS OF THE
FINDINGS: This study of practices highlights the importance of improved information regarding sexuality, fertility and reproductive health in young women with CF. A regular gynaecological follow-up and cervical screening is mandatory in this population. Better gynaecological care and contraceptive advice would help to avoid unplanned pregnancies, and optimize contraceptive selection in relationship to specific clinical conditions.
© The Author 2015. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Pap smear; contraception; counselling; cystic fibrosis; gynaecological follow-up; screening

Mesh:

Year:  2015        PMID: 26345688     DOI: 10.1093/humrep/dev217

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  4 in total

1.  Reduced bone volumetric density and weak correlation between infection and bone markers in cystic fibrosis adult patients.

Authors:  D Gensburger; S Boutroy; R Chapurlat; R Nove-Josserand; S Roche; M Rabilloud; I Durieu
Journal:  Osteoporos Int       Date:  2016-05-11       Impact factor: 4.507

Review 2.  Optimizing sexual and reproductive health across the lifespan in people with cystic fibrosis.

Authors:  Natalie E West; Traci M Kazmerski; Jennifer L Taylor-Cousar; Vin Tangpricha; Kelsie Pearson; Moira L Aitken; Raksha Jain
Journal:  Pediatr Pulmonol       Date:  2021-10-08

3.  Oral ethinyl estradiol treatment in women with cystic fibrosis is associated with lower bone mineral density.

Authors:  Malinda Wu; William R Hunt; Melissa S Putman; Vin Tangpricha
Journal:  J Clin Transl Endocrinol       Date:  2020-03-19

4.  Pregnancies and Gynecological Follow-Up after Solid Organ Transplantation: Experience of a Decade.

Authors:  Alice Bedin; Marie Carbonnel; Renaud Snanoudj; Antoine Roux; Sarah Vanlieferinghen; Claire Marchiori; Alexandre Hertig; Catherine Racowsky; Jean-Marc Ayoubi
Journal:  J Clin Med       Date:  2022-08-16       Impact factor: 4.964

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.